Intalere Teams with Ambry Genetics to Offer Healthcare Providers Advanced Genetic Testing for Cancer Risk Assessment
St. Louis (April 9, 2019) - Intalere, the healthcare industry leader in delivering optimal cost, quality and clinical outcomes, today announced a new partnership with Ambry Genetics, a leading clinical genetic testing company. The collaboration will enable Intalere to offer its healthcare providers access to state-of-the-art clinical genetic testing and family history assessment, so they may better identify and manage patients with a high risk for cancer due to an inherited genetic mutation through the Ambry CARE (Comprehensive Assessment, Risk, and Education) Program.
“Numerous studies have shown that individuals at high risk for inherited cancer are not receiving necessary and timely clinical genetic testing,” said Tom Schoenherr, chief commercial officer of Ambry Genetics. “Ambry Genetics’ CARE program is a unique, end to end, customizable program that’s designed to help healthcare systems address this problem. Through CARE, we are able to assess populations of at-risk groups, provide risk values, genetic testing if needed, and then, through genetic counseling, educate patients on how their results may impact their current and future health.”
The benefits of Ambry Genetics’ CARE program are aligned with the triple AIM of healthcare, in that they are designed to improve the patient experience, enhance the health of populations, and reduce the per capita cost of healthcare by identifying cancers early and reducing the long-term costs of patient care.
Specifically, the CARE Program will benefit providers and patients by:
- Providing personalized cancer risk information.
- Making recommendations for increased screening based on national guidelines.
- Identifying family members who may also be at risk.
- Integrating seamlessly into existing workflows.
Schoenherr stressed that the CARE program is customizable. “We understand that health systems all have unique needs and requirements, so we provide a dedicated team of specialists who evaluate where and how to best implement these programs.”
Shon Wettstein, vice president of business development at Intalere, views the partnership with Ambry as an excellent fit. “We continually seek to partner with like-minded organizations that set the highest standards in their industry,” said Wettstein. “Ambry provides unmatched accuracy and specificity in their testing, offering patients and their families the most reliable and comprehensive information to proactively evaluate risk and identify any areas of concern.”
About Ambry Genetics
Ambry Genetics is a leader in clinical diagnostic and software solutions, combining both to offer comprehensive and high-quality genetic testing. As part of the Konica Minolta family, Ambry Genetics is responsibly applying new technologies to the molecular diagnostics market to bring about precision medicine. With over 20 years of experience, Ambry Genetics has longstanding expertise in clinical genetic testing. For more information about Ambry Genetics, visit www.ambrygen.com.
Intalere’s mission focuses on elevating the operational health of America’s healthcare providers by designing tailored, smart solutions that deliver optimal cost, quality and clinical outcomes. We strive to be the essential partner for operational excellence in healthcare through customized solutions that address customers’ individual needs. We assist our customers in managing their entire spend, providing innovative technologies, products and services, and leveraging the best practices of a provider-led model. As Intalere draws on the power of our owner Intermountain Healthcare’s nationally-recognized supply chain expertise and leadership in technology, process improvement, and evidence-based clinical and business best practices, we are uniquely positioned to be the innovation leader in the healthcare industry. Visit www.intalere.com to learn more.